{"slideshow_credits": null, "snippet": "Under the terms of the deal, Bristol-Myers Squibb will pay $26 a share, 163 percent above Inhibitex's closing price on Friday.", "abstract": "Under the terms of the deal, Bristol-Myers Squibb will pay $26 a share, 163 percent above Inhibitex's closing price on Friday.", "section_name": "Business Day", "print_page": null, "document_type": "blogpost", "byline": {"person": [{"lastname": "DE LA MERCED", "rank": 1, "firstname": "Michael", "role": "reported", "organization": "", "middlename": "J."}], "original": "By MICHAEL J. DE LA MERCED"}, "web_url": "http://dealbook.nytimes.com/2012/01/07/bristol-myers-to-buy-inhibitex-for-2-5-billion/", "lead_paragraph": "Bristol-Myers Squibb agreed late on Saturday to buy Inhibitex, a maker of a hepatitis C treatment, for about $2.5 billion in cash, as major drug companies seek to bolster their pipelines with more profitable specialty products.", "headline": {"main": "Bristol-Myers to Acquire Inhibitex for $2.5 Billion", "kicker": "DealBook"}, "_id": "4fd3a2d58eb7c8105d8eb45f", "word_count": 319, "multimedia": [], "pub_date": "2012-01-07T23:48:37Z", "source": "The New York Times", "news_desk": null, "keywords": [{"name": "unknown", "value": "Bristol Myers Squibb Company|BMY|NYSE", "rank": "4"}, {"name": "organizations", "value": "Inhibitex Inc", "rank": "3"}, {"name": "organizations", "value": "Bristol Myers Squibb Company", "rank": "2"}, {"name": "unknown", "value": "Inhibitex Inc|INHX|NASDAQ", "rank": "5"}, {"name": "type_of_material", "value": "News", "rank": "1"}], "blog": [], "subsection_name": null, "type_of_material": "Blog"}